INTRODUCTION

People with mental disorders are a part of the community deserving special attention. This group is often neglected by dental professionals due to ignorance, fear, stigma, misconceptions and negative attitudes. However, they are of even more concern because there is a loss of productivity due to their disability and an increased health care cost and burden to the government and society [1]. The majority of them who required long-term psychiatric care worldwide have schizophrenia diagnosed as their primary mental disorder [2]. The prevalence of schizophrenia is less than 1% in general population, without sex differences [3]. Treatment of institutionalized residents, especially those with schizophrenia, takes up an important part of the health care resource, compared to other psychiatric inpatients [4].

Having in mind oral health, hospitalized psychiatric patients are likely to constitute a high-risk group of individuals with respect to prevalence of oral diseases and they require special attention [5]. Factors like nature of psychiatric disorders, and oral-side effects of antipsychotic medications have been noted as contributors to poor oral health among institutionalized chronic psychiatric patients [6]. In addition, unhealthy behaviors such as smoking cigarettes, alcohol consumption and drug abuse have been linked to psychiatric disorders [7].

Some studies that have been done on patients with schizophrenia focused on the assessment of dental caries and periodontal disease [8, 9, 10]. On the other hand, no published studies have addressed the prevalence of oral symptoms and disorders among inpatients with schizophrenia, or the influence of mental disorders on these conditions, although some studies recorded a high prevalence of oral symptoms and disorders, such as xerostomia, hypersalivation, recurrent oral ulcerations (RAS), burning mouth syndrome (BMS), tongue and lips disorders, oral lichen planus (OLP) etc. in psychiatric patients [11–14]. Therefore, the aim of this study was to assess the prevalence of symptoms and signs of oral disorders among inpatients with schizophrenia and to evaluate association of demographic, medical characteristics and unhealthy behaviors in this group of psychiatric inpatients with the development of oral soft tissue pathology.
METHODS

This study was conducted as an observational cross-sectional study, in accordance with the Declaration of Helsinki and it was approved by the Ethics Committee of the Dr Laza Lazarevic Clinic for Mental Disorders in Belgrade, Serbia (No. 7221), and the Faculty of Dental Medicine, University of Belgrade, Belgrade, Serbia (No. 36/10). The study is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for improving the quality of observational studies [15].

Each subject participated voluntarily in the study and was informed, through a special brochure regarding the type of research, data collection procedure, and other aspects of the study. Written consent was obtained from all subjects or their legal representatives to use personal data for research purposes. The study enrolled two groups of patients. The study group compromised 190 randomly selected patients with schizophrenia, hospitalized at the Dr. Laza Lazarevic Clinic for Mental Disorders in Belgrade, Serbia. The inclusion criteria for entering the study were that the patient was hospitalized, older than 18 years and diagnosed with schizophrenia (according to the 10. Revision of the International Classification of Diseases) two years prior to the study. Medical data for the study group patients (duration of psychiatric disease, number of hospitalizations, number and type of psychotropic medications) were taken from medical records. The exclusion criteria were a primary diagnosis of other mental disorder, hospitalized patients diagnosed with schizophrenia in the period shorter than two years from the time of the survey, the simultaneous presence of systematic diseases (e.g. nutritional deficiency, cardiovascular, respiratory, metabolic, endocrinial disorders), medications for such systematic diseases, and inability to communicate or the refusal to cooperate. The control group also comprised 190 healthy subjects suffering from aggressive periodontitis, without any psychiatric or somatic illness, who were consecutively recruited from the pool of patients at the Clinic for Periodontology and Oral Medicine, Faculty of Dental Medicine, University in Belgrade, Serbia [16]. Participants of the control did not use any medications that could affect oral health [17]. Groups were age- and sex-matched.

A questionnaire was designed for the purpose of this research with the aim of recording information on demographic data (age and sex), unhealthy habits (tobacco smoking, alcohol consumption and drug abuse), and data about the existence of any oral symptom and/or sings related to oral soft tissue pathology.

All participants were subjected to targeted clinical examinations in the dental office at the Dr Laza Lazarevic Clinic for Mental Disorders in Belgrade, Serbia (patients of the study group), and the Department of Periodontology and Oral Medicine, Faculty of Dental Medicine, University in Belgrade, Serbia (patients of the control group), according to criteria recommended by the World Health Organization [18]. The examination was performed in the following sequence: labial mucosa and labial sulci (upper and lower), labial part of the commissures and buccal mu-cosa (right and left), tongue (dorsal and ventral surfaces, margins), floor of the mouth, hard and soft palate and alveolar ridges/gingiva (upper and lower). During clinical examination, the following elements of the lesion were analyzed: anatomical location, extension; possible etiological or related factors were also recorded [19].

All collected data were organized and evaluated using dedicated software (SPSS 17.0 Inc., Chicago, IL, USA) and were analyzed by descriptive statistical parameters, methods for testing the difference of numerical data and regression models. Descriptive statistical methods were represented by measures of central tendency (mean and median), measures of variability (standard deviation and variation interval) and were expressed in percentages. The methods for testing the difference of numerical data (age) were represented by the t-test of independent groups. For testing data of different categories (sex, medications, unhealthy habits), $\chi^2$ test was used. Level of significance was set at $p < 0.05$.

RESULTS

The study group consisted of 190 hospitalized patients with schizophrenia (95 males and 95 females) aged 19–67 years, with mean age of 43.59 ± 11.96 years. Most respondents (32.1%) were in age group over 50. The control group also consisted of 190 mentally healthy subjects (95 males and 95 females) aged 19–72 years, with mean age 43.20 ± 11.89 years. Most respondents in control group (30%) were in age group between 41–50. The groups thus where comparable in terms of age ($p = 0.747$ for t-test of independent groups) and sex ($p = 1.000$ for Pearson $\chi^2$-test).

Distributions of unhealthy habits in both groups are shown in Table 1. In the study group most of the patients pleaded that they consume alcoholic beverages, in contrast to the control group who have often declared not to consume alcoholic beverages. Also, most of study group patients said that they sometimes enjoy drugs, unlike mentally healthy individuals who, in almost all cases, stated that they do not enjoy them. Among the patients of the study group, almost 75% of them smoked cigarettes; unlikely, in the control group patients there was less than half smokers.

A statistically significant difference between the two groups of participants was observed in all three observed variables in terms of practicing bad habits for oral health (Table 1).

Table 1. Distribution of unhealthy habits in both groups

| Unhealthy habits | Obtained values | Significance ($p^*$) |
|------------------|----------------|---------------------|
|                  | Study group n (%) | Control group n (%) |               |
| Smoking cigarettes: | 142 (74.7) 48 (25.3) | 75 (39.5) 115 (60.5) | <0.000* |
| yes no            |                  |                     |               |
| Alcohol consumption: | 49 (25.8) 141 (74.2) | 2 (1.1) 188 (98.9) | <0.000* |
| yes no            |                  |                     |               |
| Drug abuse:       | 133 (70) 57 (30) | 39 (20.5) 151 (79.5) | <0.000* |
| yes no            |                  |                     |               |

*statistically significant; $^*$Pearson $\chi^2$-test
Table 2. Psychotropic medications of patients in study group

| Psychotropic medications       | Obtained values Study group n (%) |
|-------------------------------|-----------------------------------|
| Antipsychotics                |                                   |
| 1) Typical antipsychotics     |                                   |
| - chlorpromazine              | 34 (17.9)                         |
| - loxapine                    | 8 (4.2)                           |
| - leponipramide               | 37 (19.5)                         |
| - fluphenazine                | 81 (42.6)                         |
| - haloperidol                 |                                   |
| 2) Atypical antipsychotics    |                                   |
| - clozapine                   | 50 (26.3)                         |
| - risperidone                 | 39 (20.5)                         |
| - quetiapine                  | 4 (2.1)                           |
| - olanzapine                  | 54 (28.4)                         |
| - sulpirid                    | 2 (1.1)                           |
| - aripiprazole                | 3 (1.6)                           |
| Mood stabilizers              | 135 (71.1)                        |
| Hypnotics                     | 63 (33.2)                         |
| Anxiolytics                   | 160 (84.2)                        |
| Antidepressants               | 15 (7.9)                          |
| Antiparkinsonics              | 110 (57.9)                        |

Table 3. Distribution of soft tissue pathology in both groups

| Oral symptoms and signs                  | Obtained values Study group n (%) | Control group n (%) | p* |
|------------------------------------------|-----------------------------------|---------------------|----|
| Presence of oral symptoms:               |                                   |                     |    |
| Burning mouth syndrome                   | 122 (67.4)                        | 50 (26.4)           | 0.000* |
| Facial pain                              | 44 (24.3)                         | 9 (4.7)             | 0.000* |
| Hypersalivation                          | 22 (12.2)                         | 0 (0)               | 0.000* |
| Xerostomia                               | 19 (10.5)                         | 2 (1.1)             | 0.000* |
| Halitosis                                | 85 (47)                           | 13 (6.8)            | 0.000* |
| Gustatory sense                          | 50 (27.6)                         | 36 (18.9)           | 0.048* |
| Dysfunction                              | 28 (15.5)                         | 5 (2.6)             | 0.000* |
| Swallowing difficulties                  | 24 (13.3)                         | 5 (0)               | 0.000* |
| Presence of oral signs:                  |                                   |                     |    |
| Lips disorders                           | 101 (55.8)                        | 20 (10.6)           | 0.000* |
| Tongue disorders                         | 23 (12.7)                         | 2 (1.1)             | 0.000* |
| Soft and hard palate disorders           | 47 (26)                           | 4 (2.1)             | 0.000* |
| Oral mucosa disorders                    | 42 (23.2)                         | 5 (2.6)             | 0.000* |

*Statistically significant; Pearson χ² test

Table 4. Logistic regression of study group patients and oral soft tissue pathology

| Observed characteristics | Obtained values significance (p) |
|--------------------------|----------------------------------|
|                          | Sex     | Age     | Duration of disease | Number of hospitalizations | Antipsychotics | Alcohol | Narcotics | Smoking |
| Burning mouth syndrome   | 0.362   | 0.620   | 0.028*               | 0.138                      | 0.655          | 0.174   | 0.180     | 0.034*  |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Facial pain              | 0.034*  | 0.904   | 0.279                | 0.486                      | 0.863          | 0.876   | 0.378     | 0.730    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Hypersalivation          | 0.203   | 0.670   | 0.733                | 0.290                      | 0.211          | 0.519   | 0.293     | 0.829    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Xerostomia               | 0.405   | 0.565   | 0.983                | 0.205                      | 0.308          | 0.705   | 0.321     | 0.643    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Halitosis                | 0.129   | 0.395   | 0.963                | 0.209                      | 0.895          | 0.133   | 0.254     | 0.743    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Gustatory sense dysfunction| 0.924  | 0.692   | 0.297                | 0.523                      | 0.994          | 0.502   | 0.419     | 0.568    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Swallowing difficulties   | 0.931   | 0.406   | 0.468                | 0.988                      | 0.793          | 0.539   | 0.908     | 0.353    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Lips disorders           | 0.890   | 0.943   | 0.959                | 0.186                      | 0.641          | 0.632   | 0.129     | 0.475    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Tongue disorders         | 0.008*  | 0.518   | 0.132                | 0.340                      | 0.864          | 0.928   | 0.970     | 0.463    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Soft and hard palate disorders| 0.771 | 0.465   | 0.320                | 0.141                      | 0.743          | 0.227   | 0.793     | 0.521    |
|                          | /       | /       | /0.012*              | /                          | /              | /       | /         | /0.005*  |
| Oral mucosa disorders    | 0.293   | 0.727   | 0.874                | 0.641                      | 0.217          | 0.527   | 0.758     | 0.534    |

*Statistically significant;  Univariate logistic regression; Multivariate logistic regression
DISCUSSION

Based on anamnesis’ data and clinical examination of oral soft tissues, a statistically significant difference was found between inpatients with schizophrenia and mentally healthy patients in the presence of symptoms and signs of oral soft tissue diseases. Most commonly reported diseases were: xerostomia (43.2%), tongue illness (23.7%) and signs of buccal mucosa diseases (22.1%), as opposed to mentally healthy patients with the majority of cases registered with halitosis (18.9%). Xerostomia or “dry mouth” was the most common oral symptom that the inpatients with schizophrenia complained, which corresponds to the results of some previous studies [14, 19]. These results should not be surprising because it is known that xerostomia and hypo-salivation may be the consequence of the application of some psychotropic medications including: first generation antipsychotics, antiparkinsonics, antidepressants, as well as anxiolytics, which are often applied to inpatients with schizophrenia in our study [19–23]. However, in a number of previous studies, xerostomia has been registered at significantly lower percentages of patients than in our research; Dangore-Khasbage et al. [24] reported xerostomia only in 13% of patients, Ujaoney et al. [25] in 22% of patients, while Morales-Chavez et al. [11] had xerostomia in only 9.23% of psychiatric patients. This can be explained by the fact that the researches concerned oral health of psychiatric patients (not only patients with schizophrenia), as well as that the patients in our study were treated with a greater number (1–3) of antipsychotics. Common habits such as smoking and alcohol consumption can cause some oral dryness [17]. The drugs most commonly implicated include antidepressants, antipsychotics, benzodiazepines, hypnotics, opioids, and substance abuse [17].

Most of inpatients with schizophrenia in this study had coated (n = 25) and black tongue (n = 12). Similar findings were also obtained in previous studies: Znegin et al. [14] found coated tongue in 8% of patients, while Bertaud-Gounot et al. [26] in 6.8% of patients. Coated tongue is a common oral-medical problem, due to accumulation of epithelial cells, residues of food and microbial debris [27]. It is well known that the coated tongue is occurring in a person with xerostomia and those who do not maintain or irregu-larly maintain oral hygiene [27]. Black tongue is a pathological change that also occurs in people who have poor oral hygiene, who smoke, have xerostomia, and consume soft and non-abrasive food [27]. In our research most of the inpatients with schizophrenia said they smoked (74.7%).

In addition, 22.1% examinees of the study group had some disease of oral mucosa, and the most common finding of RAS (n = 13) and OLP (n = 11) was consistent with the results of other investigators. Dangore-Khasbage et al. [24] reported RAS at 16% and OLP at 2% of patients; Bertaud-Gounot et al. [27] reported RAS in 12.4% of patients; Kossioni et al. [19] registered RAS in 3.6% of psychiatric patients, while Lai et al. [28] shown that olanzapine, quetiapine and sulpiride posed a higher risk of oral ulcerations among psychiatric patients, compared to the other antipsychotics. Also, it is known that RAS and OLP have psychosomatic support, highlighting the importance of anxiety, stress and depression in the development of these oral diseases. Cerqueira et al. [29] in their research indicate that psychological disorders (in particular anxiety and stress) have a high correlation with symptoms of OLP. Similar to that, Karthikeyan et al. [30] in their study indicate that stress can be a significant etiologic co-factor in OLP and RAS, which is interesting information that should be proven.

CONCLUSION

Based on the obtained risk factors for oral soft tissues diseases of schizophrenia inpatients, it can be said that schizophrenia as a mental disorder indirectly affect the condition of oral health of this group of psychiatric patients, by reducing their motivation and awareness of the importance of oral health, which is particularly emphasized in hospital conditions. Also, this research suggest that oral care of patients with schizophrenia must include periodic monitoring of dental and soft tissues, and that greater coordination between specialists of psychiatry and dentists may better serve the need of this neglect group of psychiatric patients.

Conflict of interest: None declared.

REFERENCES

1. Sangeeta UN, Rashmi S, Keshava PK. Periodontal health among non-hospitalized psychiatric patients in Mangaluru city – India. J Clin Diagn Res. 2016; 10(8):ZC40–3.
2. Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016; 12:357–73.
3. Charlson FJ, Ferrari AJ, Santomao DA, Diminic S, Stockings E, Scott JG, et al. Global epidemiology, and burden of schizophrenia: Findings from the global burden of disease study 2016. Schizophr Bull. 2018; 44(6):1195–203.
4. Harvey PD. What is so different about psychotic patients who have extremely long institutional stays? The American Journal of Geriatric Psychiatry. 2018; 26(2):198–9.
5. Yang M, Chen P, He MX, Lu M, Wang HM, Soares JC, et al. Poor oral health in patients with schizophrenia: A systematic review and meta-analysis. Schizophr Res. 2018; 2013–9.
6. Grinshpoon A, Zusman SP, Weizman A, Ponizovsky AM. Dental health and the type of antipsychotic treatment in inpatients with schizophrenia. Isr J Psychiatry Relat Sci. 2015; 52(2):114–8.
7. Đorđević V, Đukić Dejanović S, Janković Lj, Todorović Lj. Shizophrenia and oral health – Review of the literature. Balkan Journal of Dental Medicine. 2016; 20(1):15–21.
8. Kisely S. No mental health without oral health. Can J Psychiatry. 2016; 61(5):277–82.
9. Wey MC, Loh S, Doss JG, Abu Bakar AK, Kisely S. The oral health of people with chronic schizophrenia: A neglected public health burden. Aust N Z J Psychiatry. 2016; 50(7):685–94.
10. Grinshpoon A, Zusman SP, Weizman A, Ponizovsky AM. Dental Health and the Type of Antipsychotic Treatment in Inpatients with Schizophrenia. Isr J Psychiatry Relat Sci. 2015; 52(2):114–8.
11. Morales-Chavez MC, Rueda-Delgado YM, Peña-Orozco DA. Prevalence of bucco-dental pathologies in patients with psychiatric disorders. J Clin Exp Dent. 2014; 6(1):7–11.
12. Suresh KV, Shenai P, Charta L, Ronad VAA, Bilhari N, Pramod RC, et al. Oral mucosa diseases in anxiety and depression patients: Hospital based observational study from south India. J Clin Exp Dent. 2015; (1):e95–9.
13. Krunić J, Stojanović N, Ivković N, Stojić D. Salivary flow rate and hipertension. Spec Care Dentistry. 2013; 8(4):18–24.
14. Znegin AZ, Yanik K, Celenk P, Sener A, Unal-Erzurumlu ZU, Yilmaz H, Bulut N. Oral hygiene and oral flora evaluation in psychiatric patients in nursing homes in Turkey. Niger J Clin Pract. 2015; 18(6):751–6.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344–9.
16. Benza-Bedoya R, Pareja-Vasquez M. Diagnosis and treatment of aggressive periodontitis. Odontoestomatologia. 2013; 58(2):237–40.
17. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004; 15(4):221–9.
18. WHO. Oral health surveys – basic methods. World Health Organization, 2013.
19. Kossion AM, Kossionis GE, Polychronopoulou A. Variation in oral health parameters between older people with and without mental disorders. Spec Care Dentist. 2013; 33(5):232–8.
20. Morio KA, Marshall TA, Qian F, Morgan TA. Comparing diet, oral hygiene and caries status of adult methamphetamine users and nonusers: a pilot study. J Am Dent Assoc. 2008; 139(2):171–6.
21. Thomas A, Lavrentzou E, Karouzos C, Kontis C. Salivary flow rate and oral health in patients with schizophrenia on chlorpromazine therapy. Journal of Dental Science. 2013; 8(4):18–24.
22. Hede B. Oral health in Danish hospitalized psychiatric patients. Community Dent Oral Epidemiol. 1995; 23(1):44–8.
23. Barnes GP, Allen EH, Parker WA, Lyong TC, Armentrout W, Cole J.S. Dental treatment needs among hospitalized adult mental patients. Spec Care Dent. 1988; 8(4):173–7.
24. Dangore-Khasbage S, Khairkar PH, Dewgekar SS, Bhowate RR, Bhave AS, Singh A, et al. Prevalence of oral mucosal disorders in institutionalized and non-institutionalized psychiatric patients: a study from AYRH hospital in central India. J Oral Sci. 2012; 54(1):85–91.
25. Ujaoney S, Motwani MB, Khairkar PH, Dewgekar SS, Bang G. Oral health status and dental treatment needs in institutionalized versus non-institutionalized psychiatric patients. Journal of Disability and Oral Health. 2010; 11(4):163–70.
26. Bernaud-Gounot V, Kovess-Masfety, Perrus C, Trohel G, Richard F. Oral health status and treatment needs among psychiatric inpatients in Rennes, France: a cross-sectional study. BMC Nursing. 2013; 13:227.
27. Janković Lj. Oralna medicina. Beograd: Zavod za udţbenike i nastavna sredstva; 2001.
28. Lai EC, Hsieh CY, Wong MB, Lin SJ, Yang YK, Yang YHK, et al. Comparative risk of oral ulcerations among antipsychotic users – population-based retrospective cohort study. Pharmacoepidemiol Drug Saf. 2015; 25(2):123–32.
29. Cerqueira IDM, Moura JR, Arsati F, De O, Lima-Asrati YB, Bittencourt RA, Freitas VS. Psychological disorders and oral lichen planus: A systematic review. J Investig Clin Dent. 2018; 9(4):e12363.
30. Kărțikeyan P, Aswath N. Stress as an etiological co-factor in recurrent aphtous ulcers and oral lichen planus. J Oral Sci. 2016; 58(2):237–40.